Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs PRLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CING Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 2–6 Matrix Metrics)

CING Overall Winner 6-Pillar Tally: CING 3 – 2 PRLD (1 Tie) Matrix Metrics: CING 2 – 6 PRLD

As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Prelude Therapeutics Incorporated (PRLD) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas PRLD carries 47.5/100 (HOLD) at $3.30 (N/M Forward P/E, -294.8% operating margin).

  • Composite vs. Pillar Nuance: While PRLD currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. CING 44.8/100 HOLD), CING captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -294.8% operating margin) and revenue trajectory (+0.0% vs. +41.0% YoY).
  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile PRLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs PRLD
CING NASDAQ Head-to-Head Winner
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $4.71 · SMA50: $4.82
PRLD NASDAQ
Prelude Therapeutics Incorporated
Pharmaceutical Preparations
$3.30
-3.23% 1D
Market Cap $275.3M
TTM Revenue $22M
Forward P/E N/M
Beta / 30D Vol 2.01β · 73% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 34.0 Fund 55.0 Flow 67.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 37
RSI-14: 37.5 · SMA20: $3.72 · SMA50: $3.92

6-Pillar Scorecard Institutional Category Breakdown (CING 3 – 2 PRLD)

Columns: Metric · CING · PRLD
1. Valuation Multiples PRLD
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 11.9x
2. Growth & Scale PRLD
Revenue Growth (YoY) +0.0% +41.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $22M
Market Cap $62.5M $275.3M
3. Profitability & Quality CING
Gross Margin N/A 100.0%
Operating Margin 0.0% -294.8%
Net Profit Margin 0.0% -269.8%
Return on Equity (ROE) -198.7% -57.7%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$21M -$33M
Cash Flow Margin N/A N/A
Net Cash / Leverage $22M Net Cash $8.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 111.1% (16th %ile) 137.6% (43rd %ile)
Put/Call OI Skew 0.07x (Call-Skewed) 6.57x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (2) vs PRLD (6)
Institutional Metric CING PRLD Criterion Row Edge
Market Capitalization
Scale
$62.5M $275.3M Larger Scale PRLD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +41.0% Higher Growth PRLD
Operating Margin (TTM)
Profitability
0.0% -294.8% Higher Margin CING
Net Profit Margin
Profitability
0.0% -269.8% Higher Margin CING
Return on Equity (ROE)
Capital Efficiency
-198.7% -57.7% Higher ROE PRLD
52-Week Range Position
Momentum
18% ($3–$12) 36% ($1–$7) Stronger Trend PRLD
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 2.01β · 73% Vol Lower Realized Risk PRLD
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite PRLD
Trailing 12M Revenue (USD)
Operating Scale
N/A $22M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 11.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) -$33M ($8.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CING +11.82 pp
CING: +9.17% · PRLD: -2.65%
3M Horizon CING +33.23 pp
CING: -9.68% · PRLD: -42.91%
6M Horizon CING +31.15 pp
CING: +8.43% · PRLD: -22.72%
1Y Horizon PRLD +80.72 pp
CING: +36.39% · PRLD: +117.11%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs PRLD. Trailing 12-month operating profitability (CING 0.0% vs PRLD -294.8%) and valuation multiples (CING N/M vs PRLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
PRLD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$22M
Gross Margin100.0%
Op. Margin-294.8%
ROE / Fwd P/E-57.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRLD BREAKDOWN
150d in phase · OBV NEUTRAL
Current IV 137.6%
IV Percentile 43rd %ile
Put/Call OI Skew 6.57x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PRLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $275.3M market capitalization and -294.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CING vs PRLD Key Questions & Quantitative Answers

As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Prelude Therapeutics Incorporated (PRLD) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas PRLD carries 47.5/100 (HOLD) at $3.30 (N/M Forward P/E, -294.8% operating margin). Composite vs. Pillar Nuance: While PRLD currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. CING 44.8/100 HOLD), CING captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -294.8% operating margin) and revenue trajectory (+0.0% vs. +41.0% YoY). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile PRLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRLD leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PRLD at +41.0% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (100.0% gross margin, -294.8% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $22M for PRLD. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRLD.

PRLD screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PRLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus PRLD (-57.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, PRLD carries 137.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 6.57x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.